BrainStorm to Present at Several Scientific and Investment Conferences
April 10 2013 - 8:26AM
Marketwired
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of
adult stem cell technologies for neurodegenerative diseases,
announced today that the company will be presenting at several
upcoming scientific and investment conferences.
Bizportal Biomed 2013 Conference On April
10th in Tel Aviv, Alon Natanson, CEO, will make a presentation
about the company's recent scientific and business developments to
institutional and life science investors at the Bizportal Biomed
2013 Conference.
Israstem On April 22nd at 10:40 a.m. in
Ramat Gan, Israel, Professor Daniel Offen, Chief Scientific
Advisor, will present a Keynote Lecture titled "Transplantation of
Mesenchymal Stromal Cells Secreting Neurotrophic Factors Shows
Safety and Initial Indications of Clinical Benefit in ALS Patients
in a Phase I/II Clinical Trial" at IsraStem, the Annual Israeli
Meeting of Translational Research on Stem Cells, Cell Therapy and
Regenerative Medicine in Industry and Academia.
ALS Canada Research Forum On May 4th in
Toronto, Ontario, Professor Daniel Offen, Chief Scientific Advisor,
will deliver a poster presentation about the results from the
recently completed Phase I/II clinical trial at the 9th Annual
Meeting of the ALS Research Forum of the ALS Society of Canada.
Oppenheimer's 14th
Annual Israeli Conference On May 12th at
13:45 in Tel Aviv, Alon Natanson, CEO, will make a presentation
about the company's recent scientific and business developments to
Israeli financial institutions at Oppenheimer's 14th Annual Israeli
Conference.
ALSTDI Webinar On May 8th at 10:00 am EST,
Dr. Yael Gothelf, VP Scientific & Regulatory Affairs, will
discuss the company's clinical trials program for NurOwn™ at a live
webinar sponsored by the ALS Therapy Development Institute. To
register for this webinar, go to: http://bit.ly/Zmk3ov.
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company
engaged in the development of first-of-its-kind adult stem cell
therapies derived from autologous bone marrow cells for the
treatment of neurodegenerative diseases. The Company holds the
rights to develop and commercialize its NurOwn technology through
an exclusive, worldwide licensing agreement with Ramot, the
technology transfer company of Tel Aviv University. For more
information, visit the company's website at www.brainstorm-cell.com.
Safe Harbor Statement - Statements in this announcement other
than historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended
to identify these forward-looking statements. The potential risks
and uncertainties include, without limitation, risks associated
with BrainStorm's limited operating history, history of losses;
minimal working capital, dependence on its license to Ramot's
technology; ability to adequately protect the technology;
dependence on key executives and on its scientific consultants;
ability to obtain required regulatory approvals; and other factors
detailed in BrainStorm's annual report on Form 10-K and quarterly
reports on Form 10-Q available at http://www.sec.gov. These factors
should be considered carefully, and readers should not place undue
reliance on BrainStorm's forward-looking statements. The
forward-looking statements contained in this press release are
based on the beliefs, expectations and opinions of management as of
the date of this press release. We do not assume any obligation to
update forward-looking statements to reflect actual results or
assumptions if circumstances or management's beliefs, expectations
or opinions should change, unless otherwise required by law.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or
achievements.
CONTACTS BrainStorm Cell Therapeutics Inc. Mr. Alon
Natanson CEO Phone: +972-3-9236384 info@brainstorm-cell.com
www.brainstorm-cell.com LifeSci Advisors, LLC Michael Rice Founding
Partner 646-597-6979 mrice@lifesciadvisors.com
www.LifeSciAdvisors.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Apr 2024 to May 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From May 2023 to May 2024